title: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.
abstract: OBJECTIVE
  A prospective, randomized, phase III study was performed to evaluate the feasibility and efficacy of concurrent weekly oxaliplatin with radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
  
  
  METHODS
  From January 2001 to January 2003, 115 patients with locoregionally advanced NPC were randomly assigned to either radiotherapy (RT) alone (56 patients) or concurrent chemoradiotherapy (CCRT; 59 patients). All patient characteristics were well balanced in both arms. CCRT with oxaliplatin 70 mg/m2 weekly was administered for six doses from the first day of RT.
  
  
  RESULTS
  All patients were eligible for toxicity and response analysis. Compliance with the protocol treatment was excellent, with 97% of patients completing all planned doses of oxaliplatin, and a lack of high-grade toxicity was observed. After a median follow-up time of 24 months, there was a significant difference in overall survival (OS), relapse-free survival (RFS), and metastasis-free survival (MFS) in favor of the CCRT arm. The 2-year OS rates were 100% for the CCRT arm and 77% for the RT arm (P = .01). The 2-year MFS rates were 92% for the CCRT arm and 80% for the RT arm (P = .02). The 2-year RFS rates were 96% for the CCRT arm and 83% for the RT arm (P = .02).
  
  
  CONCLUSIONS
  CCRT with weekly oxaliplatin is feasible and improves OS, MFS, and RFS rates in patients with locoregionally advanced NPC. Therefore, further randomized trials including oxaliplatin are warranted.
authors.affiliation: Department of Medical Oncology, Cancer Center of Sun Yat-Sen University, Guangzhou, People's Republic of China. zhangl@gzsums.edu.cn
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Chong
authors.initials: C
authors.lastname: Zhao
authors.forename: Pei-Jian
authors.initials: PJ
authors.lastname: Peng
authors.forename: Li-Xia
authors.initials: LX
authors.lastname: Lu
authors.forename: Pei-Yu
authors.initials: PY
authors.lastname: Huang
authors.forename: Fei
authors.initials: F
authors.lastname: Han
authors.forename: Shao-Xiong
authors.initials: SX
authors.lastname: Wu
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000077150:Oxaliplatin; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D018709:Statistics, Nonparametric; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin